Andreadis P, Karagiannis T, Malandris K, Avgerinos I, Liakos A, Manolopoulos A, Bekiari E, Matthews DR, Tsapas A (2018) Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metabolism 20(9):2255–2263. https://doi.org/10.1111/dom.13361

Article  CAS  Google Scholar 

Aranäs C, Edvardsson CE, Shevchouk OT, Zhang Q, Witley S, Blid Sköldheden S, Zentveld L, Vallöf D, Tufvesson-Alm M, Jerlhag E (2023) Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine, 93. https://doi.org/10.1016/j.ebiom.2023.104642

Askgaard G, Leon DA, Deleuran T, Tolstrup JS (2020) Hospital admissions and mortality in the 15 year after a first-time hospital contact with an alcohol problem: a prospective cohort study using the entire Danish population. Int J Epidemiol 49(1):94–102. https://doi.org/10.1093/ije/dyz159

Article  PubMed  Google Scholar 

Carvalho AF, Heilig M, Perez A, Probst C, Rehm J (2019) Alcohol use disorders. Lancet 394(10200):781–792. https://doi.org/10.1016/S0140-6736(19)31775-1

Article  PubMed  Google Scholar 

Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, Marchette RCN, Koob GF, Roberto M, Vendruscolo LF, Leggio L (2023) The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. https://doi.org/10.1172/jci

Clinical Trial of Rybelsus (Semaglutide) (2024) Among Adults With Alcohol Use Disorder (AUD). https://www.clinicaltrials.gov/study/NCT05892432, accessed May 13

Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ (2002) Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. In J Endocrinol (172). http://www.endocrinology.org

Díaz-Megido C, Thomsen M (2023) Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice. Psychopharmacology 240(6):1287–1298. https://doi.org/10.1007/s00213-023-06367-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder (2024) and Comorbid Obesity? (SEMALCO). https://www.clinicaltrials.gov/study/NCT05895643, accessed May 13

Effects of Semaglutide on Nicotine Intake (2024) https://www.clinicaltrials.gov/study/NCT05530577, accessed May 13

Eren-Yazicioglu CY, Yigit A, Dogruoz RE, Yapici-Eser H (2021) Can GLP-1 be a target for reward system related disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on palatable food, drugs of abuse, and Alcohol. Front Behav Neurosci 1–15. https://doi.org/10.3389/fnbeh.2020.614884

Exenatide for Smoking Cessation and Prevention of Weight Gain (2024) https://www.clinicaltrials.gov/study/NCT05610800, accessed May 13

Fink-Jensen A, Vilsbøll T (2016) Glucagon-like peptide-1 (GLP-1) analogues: a potential new treatment for alcohol use disorder? Nordic Journal of Psychiatry, vol 70. Taylor and Francis Ltd, pp 561–562. https://doi.org/10.1080/08039488.2016.1176252

Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP (1995) Distribution of GLP-1 binding sites in the rat brain: evidence that Exendin-4 is a Ligand of Brain GLP-1 binding sites. Eur J Neurosci 7(11):2294–2300. https://doi.org/10.1111/j.1460-9568.1995.tb00650.x

Article  PubMed  Google Scholar 

Holst JJ (2007) The physiology of glucagon-like peptide 1. In Physiological Reviews (Vol. 87, Issue 4, pp. 1409–1439). https://doi.org/10.1152/physrev.00034.2006

Klausen MK, Jensen ME, Møller M, Le Dous N, Jensen A-MØ, Zeeman VA, Johannsen C-F, Lee A, Thomsen GK, Macoveanu J, Fisher PM, Gillum MP, Jørgensen NR, Bergmann ML, Poulsen HE, Becker U, Holst JJ, Benveniste H, Volkow ND, Fink-Jensen A (2022a) Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight 7(19). https://doi.org/10.1172/jci.insight.159863

Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A (2022b) The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol 179(4). https://doi.org/10.1111/bph.15677

Leggio L, Hendershot CS, Farokhnia M, Fink-Jensen A, Klausen MK, Schacht JP, Simmons WK (2023) GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. In Nature Medicine. Nat Res. https://doi.org/10.1038/s41591-023-02634-8

Article  Google Scholar 

Lengsfeld S, Burkard T, Meienberg A et al (2023) Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. eClinicalMedicine 57:101865. https://doi.org/10.1016/j.eclinm.2023.101865

Article  PubMed  PubMed Central  Google Scholar 

Lund A, Knop FK, Vilsbøll T (2014) Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med Vol 25(5):407–414. https://doi.org/10.1016/j.ejim

Article  CAS  Google Scholar 

Lüthi H, Lengsfeld S, Burkard T et al (2024) Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial. eClinicalMedicine 68:102429. https://doi.org/10.1016/j.eclinm.2024.102429

Article  PubMed  PubMed Central  Google Scholar 

Palmour RM, Ervin FR, Baker GB, Young SN (1998) An amino acid mixture deficient in phenylalanine and tyrosine reduces cerebrospinal fluid catecholamine metabolites and alcohol consumption in vervet monkeys. Psychopharmacology 136(1):1–7. https://doi.org/10.1007/s002130050532

Article  CAS  PubMed  Google Scholar 

Semaglutide Therapy for Alcohol Reduction (STAR) (2024) https://clinicaltrials.gov/study/NCT06015893, accessed May 13

Semaglutide Therapy for Alcohol Reduction - Tulsa (2024) (STAR-T). https://www.clinicaltrials.gov/study/NCT05891587, accessed May 13

Semaglutide for Alcohol Use Disorder (2024) https://www.clinicaltrials.gov/study/NCT05520775, accessed May 13

Strathe A, Horn DB, Larsen MS, Rubino D, Sørrig R, Tran MTD, Wharton S, Overgaard RV (2023) A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity. Diabetes Obes Metab 25(11):3171–3180. https://doi.org/10.1111/dom.15211Epub 2023 Jul 9. PMID: 37424165

Article  PubMed  Google Scholar 

Swift RM, Aston ER (2015) Pharmacotherapy for alcohol use disorder: Current and emerging therapies. In Harvard Review of Psychiatry (Vol. 23, Issue 2, pp. 122–133). Lippincott Williams and Wilkins. https://doi.org/10.1097/HRP.0000000000000079

Thomsen M, Dencker D, Wörtwein G, Weikop P, Egecioglu E, Jerlhag E, Fink-Jensen A, Molander A (2017) The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice. Pharmacol Biochem Behav 160:14–20. https://doi.org/10.1016/j.pbb.2017.07.014

Article  CAS  PubMed  Google Scholar 

Thomsen M, Holst JJ, Molander A, Linnet K, Ptito M, Fink-Jensen A (2019) Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology 236(2). https://doi.org/10.1007/s00213-018-5089-z

Thomsen M, Holst JJ, Molander A et al (2020) Correction to: Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology 237:287. https://doi.org/10.1007/s00213-019-05374-1

Umapathysivam MM, Lee MY, Jones KL, Annink CE, Cousins CE, Trahair LG, Rayner CK, Chapman MJ, Nauck MA, Horowitz M, Deane AM (2014) Comparative effects of prolonged and intermittent stimulation of the Glucagon-Like peptide 1 receptor on gastric emptying and Glycemia. Diabetes 63(2):785–790. https://doi.org/10.2337/db13-0893

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vallöf D, MacCioni P, Colombo G, Mandrapa M, Jörnulf JW, Egecioglu E, Engel JA, Jerlhag E (2016) The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol 21(2):422–437. https://doi.org/10.1111/adb.12295

Article  CAS  PubMed  Google Scholar 

Vallöf D, Kalafateli AL, Jerlhag E (2020) Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats. Translational Psychiatry 10(1). https://doi.org/10.1038/s41398-020-00923-1

Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R (2024) Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Mol Psychiatry 1–12. https://doi.org/10.1038/s41380-024-02498-5

WHO. Global Status Report on Alcohol and Health (2018)

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989–1002. https://doi.org/10.1056/nejmoa2032183

Article  CAS  PubMed  Google Scholar 

Wium-Andersen IK, Wium-Andersen MK, Fink-Jensen A, Rungby J, Jørgensen MB, Osler M (2022) Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study. Basic Clin Pharmacol Toxicol 131(5):372–379. https://doi.org/10.1111/bcpt.13776

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yammine L, Green CE, Kosten TR et al (2021) Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial. Nicotine Tob Res. 2021;23(10):1682–1690. https://doi.org/10.1093/ntr/ntab066